抗高血压药物与牙周炎的关联:一项全面的药物向门德尔随机化研究
Quintessence international (Berlin, Germany : 1985)
|September 20, 2024
概括
循环利尿剂可能会降低牙周炎风险,而血管酶转化酶抑制剂可能会增加. 这项研究使用了门德尔的随机化来探索抗高血压药物对牙周炎的影响. 对于潜在的药物重用,需要进一步的研究.
科学领域:
- 药物基因组学 药物基因组学
- 牙周病学 牙周病学
- 心血管医学 心血管医学
背景情况:
- 牙周炎是一种常见的炎症性疾病,影响牙.
- 高血压是一种普遍的心血管疾病,通常用药物治疗.
- 抗高血压药物和牙周炎风险之间的关系尚未完全理解.
研究的目的:
- 调查抗高血压药物与患牙周炎的风险之间的因果关系.
- 利用孟德尔随机化来评估各种抗高血压药物类别对牙周炎风险的长期影响.
主要方法:
- 采用药物标的门德尔随机化方法,使用与缩血压相关的遗传变异.
- 分析了针对牙周炎 (急性和慢性) 和缩血压的大规模全基因组关联研究的数据.
- 进行了局部化分析,以确定药物点和牙周炎易感性之间共享的遗传位置.
主要成果:
- ангиотензин转化酶抑制剂与急性牙周炎的风险增加有关.
- 循环利尿剂显示慢性牙周炎的风险降低.
- thiazides 和相关的利尿剂表明对急性和慢性牙周炎都有保护作用.
结论:
- 结果表明循环利尿剂可能在牙周炎中起着保护作用,而ACE抑制剂可能会增加风险.
- 在抗高血压药物标 (ACE,SLC12A2) 和牙周炎之间发现了基因重叠.
- 需要进一步的研究来探索抗高血压药物的治疗潜力,以预防和治疗牙周炎.
相关概念视频
Antihypertensive Drugs: Direct Renin Inhibitors
508
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
508
Antihypertensive Drugs: Angiotensin II Receptor Blockers
600
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
600
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
396
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
396
Antihypertensive Drugs: Vasodilators
491
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
491
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
492
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
492
Antihypertensive Drugs: Action of β1 Blockers
314
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
314


